Biora Therapeutics develops smart pill-based therapeutic delivery platforms, including BioJet™, an orally ingestible liquid jet technology for needle-free delivery of large molecules, and NaviCap™, a targeted oral delivery platform for colon-focused treatment of inflammatory bowel disease. BIOR news has centered on platform development, drug-delivery presentations, pharma collaborator activity, clinical and regulatory updates, and operating and financial results.
Company developments also include capital-structure and governance matters tied to Biora’s court-supervised restructuring. In 2025, Biora completed the restructuring, emerged as a privately held company, and cancelled its existing common shares under its plan of reorganization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.